Models
2
Patents
3
Overview
Dominant surgical-robotics maker (NASDAQ: ISRG; founded 1995, Sunnyvale CA) of the da Vinci teleoperated surgical robots and the Ion robotic bronchoscopy system; 11,000+ da Vinci installed worldwide.
Verified record
- Verified deployments
- None on file
- Active incidents
- 51 incidents on file
DEPLOY Intelligence
Market intelligence for physical AI
Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.
Key facts
Installed base
Gating events
Stock listing
Market position
da Vinci product type
Ion product type
Hero image candidate
Data & sources
Company filings
2
Press releases
1
News coverage
1
Patent documents
3
7 sources backing this record.View all →
Models (2)
View all models →Current platform
Ion Endoluminal System
Intuitive Surgical's Ion Endoluminal System is a robotic-assisted bronchoscopy platform for minimally invasive biopsy of peripheral lung nodules. It uses an ultra-thin, shape-sensing maneuverable catheter with PlanPoint CT-based airway planning to reach lesions deep in the peripheral lung. FDA 510(k) cleared in February 2019 and commercially deployed across US hospitals, with subsequent AI and advanced-imaging integration clearances.
Current platform
da Vinci (and Ion)
Intuitive Surgical (NASDAQ: ISRG; founded 1995, Sunnyvale, California) is the dominant incumbent and verified gold standard of surgical robotics. Its da Vinci platform spans the multi-port X and Xi systems, the SP single-port system, and the fifth-generation da Vinci 5, which the FDA cleared via 510(k) on March 14, 2024 with a headline Force Feedback sensing feature, alongside the Ion endoluminal robotic bronchoscopy system cleared in February 2019. As of its SEC Form 10-Q for the quarter ended March 31, 2026, the verified installed base was 11,395 da Vinci systems, up 12 percent year over year and including 1,464 da Vinci 5 units, plus 1,041 Ion systems, up 22 percent, with worldwide procedures growing about 17 percent. Surgical robotics sits in the registry as a deliberate axis-extension: physical AI operating in the medical regulatory regime, where FDA clearance is the verified gating event for maturity, and Intuitive clears it across multiple platforms and generations, placing it at production maturity. On AI substance, da Vinci is a master-slave teleoperated system with shipped analytics-grade AI such as Case Insights and machine-vision interface features, and Force Feedback is a shipped sensing feature rather than autonomy; autonomous suturing and tissue manipulation via vision-language models are research demonstrations on da Vinci hardware, not shipped features, and the 4,000-mile telesurgery demonstration is investigational. The widely cited 43-percent-less-force figure is preclinical and marketing-sourced rather than an outcomes-verified clinical result.
Explainers
Plain-language answers to the questions people ask about Intuitive Surgical, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.
- What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.
- What is Intuitive Surgical and the da Vinci surgical robot?
Intuitive Surgical is the verified-at-scale anchor of the surgical robotics cohort. Per SEC 10-Q registry source-of-truth, installed base is 11,395 da Vinci systems + 1,041 Ion systems; the installed base dwarfs combined competitor installed base. da Vinci 5 was FDA-cleared March 2024 as the current product generation; Ion is a separate robotic-bronchoscopy product line. Architecture is teleoperated baseline with shipped analytics AI; autonomous suturing work on da Vinci hardware is research demos, not shipped product. Maturity: production. Per DEPLOY's framework, da Vinci is the gold standard verified deployment all other surgical entrants are measured against.
- How does DEPLOY track the 2026 da Vinci SureForm gray-reload Class I recall?
DEPLOY tracks the [2026 da Vinci SureForm gray-reload Class I recall](https://registry.deploy.report/incidents/davinci-sureform-gray-reload-recall-death-2026) at primary-source-anchored FDA-recall-database verification depth as the surgical cohort's most severe verified incident. The substrate: 8mm SureForm 30 Gray reloads (2mm staples for extra-thin tissue) produced incomplete staple lines on blood vessels despite a 'completed' fire indication; customer letter / quarantine March 11, 2026; FDA classified Class I (reported May 2026); 1 death + 4 serious injuries (bleeding). Blue/white reloads UNAFFECTED at canonical within-product-family verification scope distinction. The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1 (severity=critical at primary-source-anchored verification; cohort's most severe); within-entity verification scope at sub-product-line granularity (gray vs blue/white reload distinction is the within-da-Vinci feature-level verification posture distinct); regulatory clearance per jurisdiction at Dim 4 (FDA Class I primary-government-record sub-tier verification); year-discipline framework distinguishing the 2026 gray-reload recall from the 2022 SureForm fragment recall (Z-0340-2023; Class II; October 7, 2022) at year-class-failure-mode granularity. Cap-flag honest-absence at exact recall Z-number + unit count (not captured from primary FDA pages). Root cause stated 'still under investigation' at primary-source-anchored verification depth.
- How does DEPLOY track incident outcome_class and deployment exposure_hours at actuarial depth?
DEPLOY tracks Phase 3 Dim 1 actuarial substrate at primary-source-anchored verification depth across two structurally-distinct axes simultaneously: incident numerator (outcome_class at 67 rows across 61 incidents; multi-class where evidenced; distribution skewed regulatory_action:34 + property_damage:18 + bodily_injury:7 + no_outcome:4 + financial_loss:2 + fatality:1 + near_miss:1) and deployment denominator (exposure_hours at canonical 128-nulls honest-absence; Agent A documented under-population over fabrication). The 128-nulls is the canonical worked example for 'honest absence at full-population scale beats partial fabrication.' Scalar selectivity tight per *_basis verified-vs-claimed discipline: 1 USD figure at primary-source-anchored verification depth (MQ-9 Reaper $32M reported_press gt_10m); 3 fatality_count rows; 5 bodily_injury_severity rows; 4 loss_cost_class rows; most NULL at honest-absence cap-flag. Cap-flag-as-trust-signal operates recursively at three substantive layers simultaneously: 128-null exposure_hours denominator (full-population honest-absence) + scalar selectivity at 1-of-61 USD verified ratio (extreme primary-source-anchored selectivity) + outcome distribution skew (no_outcome:4 documented as substantive editorial state, not as substrate-completeness gap). The framework operates at honesty-as-strength rather than coverage-as-strength: under-population at primary-source-anchored verification depth beats fabrication at marketing-aggregation depth. Rover's 5-commit Dim 1 surface work landed across all four axes (callable MCP tool + structured JSON-LD + human-facing /incidents page + REST aggregated endpoint); substrate is fully live and queryable.
- How does DEPLOY distinguish da Vinci safety events at year-class-failure-mode-product-variant granularity?
DEPLOY tracks within-da-Vinci-product-family safety events at year-class-failure-mode-product-variant granularity per Agent A's surgical incidents substrate. The three canonical worked examples span distinct product lines + distinct years + distinct classes + distinct failure modes simultaneously: [2013 EndoWrist Hot Shears Class I recall](https://registry.deploy.report/incidents/davinci-hot-shears-burn-recall-2013) (May 8, 2013 Urgent Medical Device Notification; '-09'/'-10' versions; insulation micro-cracks near distal shaft after cleaning/sterilization create monopolar energy arc path; burn tissue outside surgical field; 134 tip-cover complaints + 82 MDRs Jan 2010-Dec 2011; remediated via instrument version supersession; load-bearing historical da Vinci safety event); [2022 SureForm fragment Class II recall](https://registry.deploy.report/incidents/davinci-sureform-stapler-fragment-recall-2022) (Z-0340-2023; October 7, 2022; da Vinci Xi 8mm SureForm 30 curved-tip staplers and reloads; intraoperative device-fragment generation; potential staple deployment failure); [2026 SureForm gray-reload Class I recall](https://registry.deploy.report/incidents/davinci-sureform-gray-reload-recall-death-2026) (March 11, 2026 customer letter + Class I reported May 2026; 8mm SureForm 30 Gray reloads; incomplete staple lines on blood vessels; 1 death + 4 serious injuries; cohort's most severe per [the 2026 gray-reload framework-in-action narrative](/explainers/how-deploy-tracks-the-2026-davinci-sureform-gray-reload-class-i-recall)). Plus adjacent [2013 FDA Warning Letter regulatory_action](https://registry.deploy.report/incidents/intuitive-fda-warning-letter-2013) (July 19, 2013; distinct from May 2013 device recall; reporting-compliance regulatory action; serious severity; cap-flag honest-absence at primary FDA letter direct retrieval). Aggregator coverage frequently collapses 'da Vinci recalls' across years; the framework distinguishes them structurally at four substrate axes simultaneously (year + class + failure mode + product variant) per [verified-vs-claimed at within-entity granularity methodology pillar](/explainers/verified-vs-claimed-within-entity).
Current leadership (3)
- Jaime Wong SVP & Chief Medical OfficerIR-verified
- Jamie Samath executiveSEC-verified
- David Rosa President & CEOsince 2025-04-01IR-verified
Founders (3)
- Frederic Mollcofounderfounded 1995-01-01no longer at company
- John Freundcofounderfounded 1995-01-01no longer at company
- Robert Youngecofounderfounded 1995-01-01no longer at company
Board (3)
- Gary Guthart chair
- Dave Rosa director
- Craig Barratt director
Former / Previously (4)
- Robert Younge Co-founder (first CTO)secondary-verified
- John Freund Co-foundersecondary-verified
- Gary Guthart CEO (2010-2025)IR-verified
- Frederic Moll Co-founder1995 to 2002secondary-verified
Safety record
45 recalls and 6 incidents on record (1 catastrophic, 4 critical, 38 serious, 7 moderate, 1 minor). Most recent: Jun 2026.
Most recent: Jun 2026
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting Intuitive Surgical (51)
- Intuitive Surgical recalls da Vinci SP1098 instrument2026-06-22 · Recall
- Intuitive Surgical recalls 8mm SureForm 30 Gray Reloads after patient death2026-05-28 · Recall
- Intuitive Surgical recalls da Vinci staplers after death and injuries2026-04-15 · Recall
- Intuitive Surgical da Vinci 5 receives FDA clearance for cardiac procedures2026-01-26 · Regulatory action
- Intuitive recalls da Vinci X systems over a high rate of ACJ board failure2018-03-07 · Recall
- FDA warning letter to Intuitive Surgical over late reporting of da Vinci corrections and adverse events2013-07-19 · Regulatory action
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Recent coverage
Intuitive Surgical in third-party press
Intuitive Surgical’s Stock Has Fallen Over 25% This Year, but Goldman Sachs Still Recommends Investors Buy - NAI500
Goldman Sachs Says the Crowd Is Wrong on This Beaten-Down Medical Robotics Giant - The Motley Fool
Here's Exactly Why Intuitive Surgical Stock Is Floundering in 2026 - The Globe and Mail
Peer companies
- Johnson & Johnson3 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
- Vantis2 models
Supplied by (1)
Actuators & motors
- Harmonic Drivevia da Vinci (and Ion)Harmonic Drive strain-wave gearboxes -- EndoWrist instrument wrist joints and robotic arm transmissionssupplies
Inbound supply edges feeding this company directly or via the models it owns. Same source bar as the outbound view (verified against at least two strong sources).
Financial state
- Reporting period
- 2024-01-01 to 2024-12-31
- Reporting basis
- sec_10k
- Revenue disclosed
- $8352100000 (sec_10k)
- Lifecycle stage
- mature
- Counterparty risk class
- low
- SEC filing
- 10-K
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Regulatory filings (16)
- fda_recallfda recall · us_fdasuperseded
- Z-1232-2026fda recall · us_fdarecalled
Linked models: da Vinci (and Ion)
- Z-1262-2023fda recall · us_fdarecalled
Linked models: da Vinci (and Ion)
- Z-0340-2023fda recall · us_fdarecalled
Linked models: da Vinci (and Ion)
- Z-1855-2026fda recall · us_fdarecalled2026-03-11
Linked models: da Vinci (and Ion)
- Z-1134-2026fda recall · us_fdarecalled2025-12-04
Linked models: Ion Endoluminal System
- Z-1325-2025fda recall · us_fdarecalled2025-02-26
Linked models: da Vinci (and Ion)
- Z-2720-2024fda recall · us_fdarecalled2024-07-12
Linked models: Ion Endoluminal System
- K232610fda 510k · us_fdacleared2023-08-28reported
Linked models: da Vinci (and Ion)
- Z-0106-2022fda recall · us_fdarecalled2021-08-06
Linked models: Ion Endoluminal System
- Z-0489-2021fda recall · us_fdarecalled2020-10-23
Linked models: Ion Endoluminal System
- K182188fda 510k · us_fdacleared2018-08-13
Linked models: Ion Endoluminal System
- fda_warning_letterfda warning letter · us_fdaclosed2013-07-16
Linked models: da Vinci (and Ion)
- Z-1442-2013fda recall · us_fdarecalled2013-05-08
Linked models: da Vinci (and Ion)
- fda_510kfda 510k · us_fdacleared2000-01-01
Linked models: da Vinci (and Ion)
- K990144fda 510k · us_fdacleared1999-01-19
Linked models: da Vinci (and Ion)
Patent estate (3)
- US12575898B2usptograntedassignee
- US12520995B2usptograntedassignee
- US12446982B2usptograntedassignee
Patent litigations (4)
- 1:18-cv-01359district_courtsettled · settled undisclosedas complainant2023-01-01
- 3:21-cv-03496district_courtdecided · no infringementas respondent2024-01-28
- 8:20-cv-02274district_courtsettled · settled undisclosedas respondent2022-09-01
- 5:19-cv-00055district_courtsettled · settled undisclosedas respondent2023-01-27
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Incident recordedJun 22, 2026
Intuitive Surgical recalls da Vinci SP1098 instrument
- Verified media addedVerifiedJun 8, 2026
Navigating emergency care with da Vinci surgery
- Verified media addedVerifiedJun 5, 2026
Introducing Ion by Intuitive
- Verified media addedVerifiedJun 5, 2026
da Vinci SP single-incision surgery
- Verified media addedVerifiedJun 5, 2026
da Vinci SP single-port system
Sources (4)
- https://www.sec.gov/Archives/edgar/data/0001035267/000103526726000032/isrg-20260331.htm
- https://www.sec.gov/Archives/edgar/data/1035267/000103526726000029/q126ex-991earningsrelease.htm
- https://www.globenewswire.com/news-release/2024/03/14/2846718/7637/en/Intuitive-Announces-FDA-Clearance-of-Fifth-Generation-Robotic-System-da-Vinci-5.html
- https://www.therobotreport.com/intuitive-demos-4000-mile-telesurgery-with-da-vinci-5-surgical-robot/
Common questions
- What is Intuitive Surgical?
- Dominant surgical-robotics maker (NASDAQ: ISRG; founded 1995, Sunnyvale CA) of the da Vinci teleoperated surgical robots and the Ion robotic bronchoscopy system; 11,000+ da Vinci installed worldwide.
- What does Intuitive Surgical make?
- Intuitive Surgical has 2 robot models on the DEPLOY registry: Ion Endoluminal System, da Vinci (and Ion) (Intuitive Surgical builds both physical robots and the AI that runs them).
- Is Intuitive Surgical publicly traded?
- Yes. Intuitive Surgical is publicly traded on public markets, per the DEPLOY registry.
- Who competes with Intuitive Surgical?
- On the DEPLOY registry, peer companies to Intuitive Surgical building in the same form factors include Johnson & Johnson, LEM Surgical, MicroPort MedBot, Neocis.
- Who is the CEO of Intuitive Surgical?
- David Rosa is the ceo of Intuitive Surgical, per the DEPLOY registry.
- How can I invest in Intuitive Surgical?
- Intuitive Surgical is publicly traded (public markets), so its shares can be bought through any broker.
- Where is Intuitive Surgical headquartered?
- Intuitive Surgical is headquartered in Sunnyvale, California, USA.
- Who owns Intuitive Surgical?
- Intuitive Surgical is publicly held by its shareholders.
- Where does Intuitive Surgical operate robots?
- Intuitive Surgical is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- Is Intuitive Surgical a top robotics company?
- On DEPLOY's intelligence score, which blends verified deployments, funding, hiring, media, safety, and IP signals, Intuitive Surgical ranks in roughly the top 32% of companies tracked by the registry.
- Are there any incidents involving Intuitive Surgical?
- 51 active incidents involving Intuitive Surgical are on the DEPLOY registry. Each is a sourced, append-only record; retracted incidents are suppressed from this view.
- Is Intuitive Surgical safe?
- Intuitive Surgical has 51 active incidents on record in the DEPLOY registry. 45 recalls and 6 incidents on record (1 catastrophic, 4 critical, 38 serious, 7 moderate, 1 minor). Most recent: Jun 2026. Retracted incidents are excluded from this count.
Methodology: Verified · 4 sources (3 primary) · last reviewed 2026-07-18
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-18
Sources by quality tier
- 2
- primary-sec-filing
- SEC filing
- 1
- primary-company-ir
- Company IR disclosure
- 1
- secondary-trade-publication
- Trade publication
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Intuitive Surgical.Peer companies
- Johnson & Johnson3 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
- Vantis2 models
In the press
Recent coverage mentioning Intuitive Surgical from third-party publications. Automatically surfaced; not part of the verified registry record.
Intuitive Surgical’s Stock Has Fallen Over 25% This Year, but Goldman Sachs Still Recommends Investors Buy - NAI500
<a…
Goldman Sachs Says the Crowd Is Wrong on This Beaten-Down Medical Robotics Giant - The Motley Fool
<a…
Here's Exactly Why Intuitive Surgical Stock Is Floundering in 2026 - The Globe and Mail
<a…
In a First, a Humanoid Robot Performed Live Surgery Under a Surgeon’s Control - SingularityHub
<a…
Intuitive Surgical Has +35% Upside: A Compelling Buy Story Before July 16 - 24/7 Wall St.
<a…
Medicaroid wins Europe’s CE mark for Hinotori surgical robot - MedTech Dive
<a…
Top surgical robotics stories in the first half of 2026 - MedTech Dive
<a…
Top surgical robotics stories in the first half of 2026
The surgical robotics market grew more competitive in H1 2026, with Medtronic, Stryker, CMR Surgical, and Distalmotion introducing new platforms challenging Intuitive Surgical's…
[Report] Intuitive Surgical’s Da Vinci 5 Robot Lets Reporter Feel Organs in Real Time - 동아사이언스
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE9WZGVpYVl2X0ItbFRUalVENTVSa1FpZm1WV3RKMWNMWW9WMm9ORENCR0lrYmYxM1Rrdmc4UnRfcXZXWE5OZXZMRXgycGhPaHg3V1lLcg?oc=5"…
Intuitive Surgical Stock Is Up Over 400%. Here's Why It's Still a No-Brainer Buy. - The Motley Fool
<a…
Intuitive Surgical Stock Is Up Over 400%. Here's Why It's Still a No-Brainer Buy. - Yahoo Finance
<a…
Alva Industries raises EUR 16M for electric motor technology
Alva Industries raised EUR 16M to scale breakthrough electric motor technology for surgical robotics.
Machine-readable surfaces
- Markdown mirror: /companies/intuitive-surgical.md
- RSS feed: /companies/intuitive-surgical/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/e5127536-0ff2-4f0e-8488-64994cb2ffc7
- Revision history: /companies/intuitive-surgical/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Johnson & Johnson3 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
- Vantis2 models
Video
The da Vinci® robotic surgical system is an innovative, minimally invasive procedure. Learn more about the da Vinci robotic surgical system by watching it in ac
The da Vinci SP enables surgeons to deliver robotic surgery through a single port or incision. Watch a demo of its unique and innovative features in action. Su
Da Vinci Xi Surgical System by Intuitive PN 1004941 US REV D 11/2015
See how the Ion robotic-assisted bronchoscopy by Intuitive makes it possible to reach and biopsy difficult-to-reach nodules in the peripheral lung. Subscribe
Take a tour of Intuitive’s manufacturing facility to see inside the robot. Find out how people and processes come together to make da Vinci surgical systems.
From a hysterectomy to colon surgery to prostate cancer surgery. If your doctor has recommended surgery, robotic-assisted surgery with Intuitive's da Vinci Surg
Robotic surgery has been a reimagining of what minimally invasive surgery looks like. Drs. Amanda Pysher and Tanuja Damani explain what robotic surgery with da
* Intended for US audience. Dive into the future of surgery with Iman Jeddi, senior vice president of da Vinci platforms, as she presents the transformative
An introduction to robotic-assisted surgery if a doctor has recommended surgery and robotic-assisted surgery may be an option. Learn more about what to expect o
Reality vs attention
Intuitive Surgical draws attention at the 99th percentile but verifies reality at the 88th percentile among surgical robots. Hype Gap +11.3, 12th widest among surgical robots.
6-month trend
Analysis
Broad public reach with 1.6M video views. Strong deployment footprint with 8 operational sites across 4 countries. 2 incidents recorded in the past 90 days.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 19, 2026